Home Discoveries Services Partners Contact

Bio: Terry Wright  

Terry Wright: scientist and researcher, USA

Began his work with Physio Control, testing groundbreaking technologies for medical electronic devices, including Electro Cardiometry, in vivo oximetry, hand held ultrasound devices, defibrillators, advance warning lethal re-entrant waveform detectors and analyzers, peritoneal dialysis systems, scanning ultra-sound imagers etc. All of the devices he contributed to or created are in daily use in hospitals all over the world today. He developed new algorithms for evaluation of EKG signals which made possible the creation of implantable defibrillators, self-activating defibrillators and critical care monitors all of which save thousands of lives every month around the world.

At Monaco Medical Supplies, he went on to Design and supervise the implementation of designs for three new medical devices for transcutaneous monitoring of body parameters for space applications to be used by N.A.S.A. These devices allowed the external monitoring of blood oxygen levels, respiration depth and rate and heart rate. He supervised the programming for computer evaluation of physical parameters monitored by the devices. Oversaw and guided the transition from basic to pascal coding for the computer interface, which stabilized the performance of the system, and designed a new analogue to digital convertor for detection.

He was a staff member of Washington State University where he designed and created programs in two languages for analysis of X-Ray diffraction spectrometry studies and several other research projects in the Chemistry and Physics departments.

At ZAO Medical he re-designed the computer interface, it was the first computer aided spirometer. This device reduced the time needed to do evaluation of pulmonary function, which reduced the load on nursing staff and doctors by hundreds of thousands of man hours per year.

He was commissioned to trouble shoot medical manufacturing companies in England, France, Denmark and Germany. There he resolved life threatening issues on faulty equipment designs in order to get the relevant companies back into production. Interfaced with controlling agencies in various countries to prove resolution of faults in order to resume manufacture of equipment.

During this time, he helped in the development of trans-oesophageal cardiac output monitoring technology, the Dynavein electrical stimulator to reduce post-operative thrombosis, especially in the femoral artery. The Dynavein saves lives daily, and the trans-oesophageal cardiac output monitor has replaced Swan Ganz catheters, reducing the incidence of induced ventricular fibrillation.

In the 1990’s he retired from the medical industry and started a successful 6 figure computer company. They operated security and firewalls, maintained name, mail and web servers for their customers.

In 2006 after the death of his mother due to throat and head cancer he decided to go back into the medical industry.  His partner asked him if he could create a molecule to use PDT in Australia. After researching it for months he felt he could make a significant contribution in the field of PDT. Over four years he developed a technique for producing selective degrees of sulphonation of phthalocyanine, a highly desirable molecule for photodynamic therapy. Leeds university had spent three years trying to accomplish this unsuccessfully. He took on the challenge to make it successful.  He created the world’s first nano-molecular photosensitiser, which makes PDT possible in environments with high levels of UV, and also makes it possible to treat large internal tumours transcutaneously without excessive damage to the derma. He implemented a protocol designed to establish an immune response to cancer and has successfully tested it in first human trials working with several doctors around Australia. This technology has the capacity to save thousands of lives a year in cancer, improve the lives of people who suffer from multiple sclerosis, diabetes, psoriasis and other autoimmune disorders. It is also invaluable in treating unstoppable bacterial like MRSA and pseudomonas.

Today he is Head of Research at Cytoluminator Philippines. He was invited to the Philippines at the invitation of the Philippines Department of Health to continue his work with PDT. Over the these years he has made advancement in the treatment of cancer with continued research in PDT and synergistic medications and devices. He has worked together with his associate Dr Victor Garcia to identify and test hundreds of purported adjuvants to cancer treatment and discovered 8 that are helpful and synergistic.

Additionally, he has developed additional nanomolecules which, when used as part of a comprehensive protocol, have the ability to shut down advanced metastatic cancer in only a few days. While most research has been done using gold or carbon to make nanoparticles, these are not normal to the body, so he used a nanoparticle that looks like glucose and positively charged. Cancer readily sucks it in. Using his nanotechnology research, he has developed three nanoparticle solutions aimed directly at stopping cancers, and killing them. The third is directly designed to kill bacteria, viruses, and fungus which are always seen inside and outside cancer cells.

He has in the past 4 years developed three nanoparticle solutions in addition to our nanoparticle sensitizer used for our PDT. Two of the nanoparticle solutions are aimed directly at stopping cancers and killing them, the third is directly designed to kill bacteria, viruses and fungus which are always seen inside and outside cancer cells. 

He continues to research in this field.

His mind is always active and during all his work he has had time to assist others in high-tech projects.

Consulted to a consulting firm working for Lawrence Livermore Laboratories to create a system for refining nuclear waste safely. This project was called the MARS project, for Material Analysis and Refinement System. He designed the pumping system to reduce the air pressure to 10 micro torrs and took part in the design of the cryogenic super magnets to separate radioactive material from other materials by utilizing paramagnetism in a high speed jet of material.

 Overcame theoretical seismic monitoring limitations to make it possible to instrument Mt. Baker in Washington State USA for lava motion. It was previously considered impossible because the harmonics set up between the mountain and the ice mantle were in the same frequency domain and were 10,000 times higher amplitude than the actual lava induced seismic activity. He resolved this by creating a phased array of accelerometers and subtracting or adding signals based on the direction of orientation.

Designed a deep space accelerometer head which was used by NASA as part of the guidance system for the Viking mission to mars. Accelerometers of the time were inadequate, because the near zero temperatures froze the suspension wires of the sensor head. Sundstrad Data Control, then known as Jet Propulsion Laboratory, had contracted to NASA to resolve the issue but were unable to find a solution. His solution was to start with a crystalline substance, already frozen as far as it could get. He used crystalline quartz, etched with triple distilled water, to create a support structure which would not change characteristics over temperature.

Consulted for General Electric when the FDA shut them down because of deaths associated with problems in their defibrillator design. Their engineering team had failed to resolve the problem, so they brought me in. He modified their design to reduce the energy dissipated in their toroidal cores for the inverter by changing the switching parameters, and reduced the load by increasing the efficiency of their overall design by creating a capacitor design which incorporated the inductance necessary for wave shaping in the physical design of the capacitor, which reduced total energy requirements to deliver 320 joules in 60 milliseconds.

Consulted for 3M on the design of a continuous wave single transducer design for ultrasonic sensing. This was previously widely held to be impossible due to the signal to noise ratios. He overcame the theoretical limits by using the characteristics of a unique lead metaniobate piezoelectric as an extremely high q filter element within the transducer itself, thereby discriminating against transients and allowing mixing of transmitted and received signals within the ceramic itself before processing by higher noise elements.

Refined the design of an ultrasonic transducer array for a French company Ensonique to resolve production problems, reduce cost by 90%, and increase the reliability 100 fold. He accomplished this by specifying a custom piece of piezoelectric ceramic, to be manufactured to a different Q factor and laser machined, then diamond lapped to removed damaged material prior to polarization.

Designed a custom trans-oesophageal Doppler transducer for a cardiac output monitor for an English company. They had been previously unable to obtain the proper correlation between their design and a Swan Ganz catheter in measuring wedge pressure extrapolation. The error was in the focusing, consistency in placement and positioning, and significant return signal errors. His design resolved the problems and made that technology a reality.


Copyright © Cyto-Research  2015-2019. All rights reserved.

DISCLAIMER: Cyto-Research makes no representations or warranties, express or implied, as to the accuracy, completeness, usefulness or and other reason not mentioned of Cyto-Research website, social comments or any other media or method of communication by Cyto-Research, any content and to the extent allowed by law; Cyto-Research expressly disclaims all warranties, expressed or implied, including without limitation implied warranties of merchantability and fitness for any purpose whatsoever. You shall assume all risk associated with the use of Cyto-Research website and of any content or communication, including but not limited to any other type of communication not listed herein; Cyto-Research does not assume any risk and shall have no liability whatsoever for your use of the website or any content therein. Cyto-Research will have the right at any time to change content and Cyto-Research is not responsible for any incorrect or inaccurate content.  The use of the Cyto-Research website or any of its content does not create or express or imply any doctor/patient relationship with any doctor, clinic, hospital or other facility mentioned or included in content herein. Cyto-Research is not liable for contacting or follow up timeliness. In no event will Cyto-Research be liable to you in any manner whatsoever for any decision made by you, or action made by you, or non-action taken by you based on any content herein
FOR ALL UNITED STATES VISITORS: FDA Required Disclaimer For Sites That Do Not Endorse Chemotherapy:
This web site is for educational purposes only. It is not intended as a substitute for the diagnosis, treatment and advice of a qualified licensed professional. This site offers people medical information and tells them their alternative medical options, but in no way should anyone consider that this site represents the “practice of medicine.” This site assumes no responsibility for how this material is used. Also note that this website frequently updates its contents, due to a variety of reasons, therefore, some information may be out of date. The statements regarding alternative treatments for cancer have not been evaluated by the FDA.